Molecular pharmacology and antitumor activity of PHT-427, a novel akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor

Emmanuelle Meuillet, Song Zuohe, Robert Lemos, Nathan Ihle, John Kingston, Ryan Watkins, Sylvestor A. Moses, Shuxing Zhang, Lei Du-Cuny, Roy Herbst, Jörg J. Jacoby, Li Li Zhou, Ali M. Ahad, Eugene A Mash, D. Lynn Kirkpatrick, Garth Powis

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Phosphatidylinositol 3-kinase/phosphatidylinositide-dependent protein kinase 1 (PDPK1)/Akt signaling plays a critical role in activating proliferation and survival pathways within cancer cells. We report the molecular pharmacology and antitumor activity of PHT-427, a compound designed to bind to the pleckstrin homology (PH) binding domain of signaling molecules important in cancer. Although originally designed to bind the PH domain of Akt, we now report that PHT-427 also binds to the PH domain of PDPK1. A series of PHT-427 analogues with variable C-4 to C-16 alkyl chain length were synthesized and tested. PHT-427 itself (C-12 chain) bound with the highest affinity to the PH domains of both PDPK1 and Akt. PHT-427 inhibited Akt and PDPK1 signaling and their downstream targets in sensitive but not resistant cells and tumor xenografts. When given orally, PHT-427 inhibited the growth of human tumor xenografts in immunodeficient mice, with up to 80% inhibition in the most sensitive tumors, and showed greater activity than analogues with C4, C6, or C8 alkyl chains. Inhibition of PDPK1 was more closely correlated to antitumor activity than Akt inhibition. Tumors with PIK3CA mutation were the most sensitive, and K-Ras mutant tumors were the least sensitive. Combination studies showed that PHT-427 has greater than additive antitumor activity with paclitaxel in breast cancer and with erlotinib in non-small cell lung cancer. When given >5 days, PHT-427 caused no weight loss or change in blood chemistry. Thus, we report a novel PH domain binding inhibitor of PDPK1/Akt signaling with significant in vivo antitumor activity and minimal toxicity.

Original languageEnglish (US)
Pages (from-to)706-717
Number of pages12
JournalMolecular Cancer Therapeutics
Volume9
Issue number3
DOIs
StatePublished - Mar 2010

Fingerprint

Protein Kinases
Pharmacology
Phosphotransferases
Neoplasms
Heterografts
Phosphatidylinositol 3-Kinase
Pleckstrin Homology Domains
4-dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide
Paclitaxel
Non-Small Cell Lung Carcinoma
Weight Loss
Breast Neoplasms
Mutation
Survival
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Molecular pharmacology and antitumor activity of PHT-427, a novel akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. / Meuillet, Emmanuelle; Zuohe, Song; Lemos, Robert; Ihle, Nathan; Kingston, John; Watkins, Ryan; Moses, Sylvestor A.; Zhang, Shuxing; Du-Cuny, Lei; Herbst, Roy; Jacoby, Jörg J.; Zhou, Li Li; Ahad, Ali M.; Mash, Eugene A; Kirkpatrick, D. Lynn; Powis, Garth.

In: Molecular Cancer Therapeutics, Vol. 9, No. 3, 03.2010, p. 706-717.

Research output: Contribution to journalArticle

Meuillet, E, Zuohe, S, Lemos, R, Ihle, N, Kingston, J, Watkins, R, Moses, SA, Zhang, S, Du-Cuny, L, Herbst, R, Jacoby, JJ, Zhou, LL, Ahad, AM, Mash, EA, Kirkpatrick, DL & Powis, G 2010, 'Molecular pharmacology and antitumor activity of PHT-427, a novel akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor', Molecular Cancer Therapeutics, vol. 9, no. 3, pp. 706-717. https://doi.org/10.1158/1535-7163.MCT-09-0985
Meuillet, Emmanuelle ; Zuohe, Song ; Lemos, Robert ; Ihle, Nathan ; Kingston, John ; Watkins, Ryan ; Moses, Sylvestor A. ; Zhang, Shuxing ; Du-Cuny, Lei ; Herbst, Roy ; Jacoby, Jörg J. ; Zhou, Li Li ; Ahad, Ali M. ; Mash, Eugene A ; Kirkpatrick, D. Lynn ; Powis, Garth. / Molecular pharmacology and antitumor activity of PHT-427, a novel akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. In: Molecular Cancer Therapeutics. 2010 ; Vol. 9, No. 3. pp. 706-717.
@article{e94732faf295471590f4225a2ce7f592,
title = "Molecular pharmacology and antitumor activity of PHT-427, a novel akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor",
abstract = "Phosphatidylinositol 3-kinase/phosphatidylinositide-dependent protein kinase 1 (PDPK1)/Akt signaling plays a critical role in activating proliferation and survival pathways within cancer cells. We report the molecular pharmacology and antitumor activity of PHT-427, a compound designed to bind to the pleckstrin homology (PH) binding domain of signaling molecules important in cancer. Although originally designed to bind the PH domain of Akt, we now report that PHT-427 also binds to the PH domain of PDPK1. A series of PHT-427 analogues with variable C-4 to C-16 alkyl chain length were synthesized and tested. PHT-427 itself (C-12 chain) bound with the highest affinity to the PH domains of both PDPK1 and Akt. PHT-427 inhibited Akt and PDPK1 signaling and their downstream targets in sensitive but not resistant cells and tumor xenografts. When given orally, PHT-427 inhibited the growth of human tumor xenografts in immunodeficient mice, with up to 80{\%} inhibition in the most sensitive tumors, and showed greater activity than analogues with C4, C6, or C8 alkyl chains. Inhibition of PDPK1 was more closely correlated to antitumor activity than Akt inhibition. Tumors with PIK3CA mutation were the most sensitive, and K-Ras mutant tumors were the least sensitive. Combination studies showed that PHT-427 has greater than additive antitumor activity with paclitaxel in breast cancer and with erlotinib in non-small cell lung cancer. When given >5 days, PHT-427 caused no weight loss or change in blood chemistry. Thus, we report a novel PH domain binding inhibitor of PDPK1/Akt signaling with significant in vivo antitumor activity and minimal toxicity.",
author = "Emmanuelle Meuillet and Song Zuohe and Robert Lemos and Nathan Ihle and John Kingston and Ryan Watkins and Moses, {Sylvestor A.} and Shuxing Zhang and Lei Du-Cuny and Roy Herbst and Jacoby, {J{\"o}rg J.} and Zhou, {Li Li} and Ahad, {Ali M.} and Mash, {Eugene A} and Kirkpatrick, {D. Lynn} and Garth Powis",
year = "2010",
month = "3",
doi = "10.1158/1535-7163.MCT-09-0985",
language = "English (US)",
volume = "9",
pages = "706--717",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Molecular pharmacology and antitumor activity of PHT-427, a novel akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor

AU - Meuillet, Emmanuelle

AU - Zuohe, Song

AU - Lemos, Robert

AU - Ihle, Nathan

AU - Kingston, John

AU - Watkins, Ryan

AU - Moses, Sylvestor A.

AU - Zhang, Shuxing

AU - Du-Cuny, Lei

AU - Herbst, Roy

AU - Jacoby, Jörg J.

AU - Zhou, Li Li

AU - Ahad, Ali M.

AU - Mash, Eugene A

AU - Kirkpatrick, D. Lynn

AU - Powis, Garth

PY - 2010/3

Y1 - 2010/3

N2 - Phosphatidylinositol 3-kinase/phosphatidylinositide-dependent protein kinase 1 (PDPK1)/Akt signaling plays a critical role in activating proliferation and survival pathways within cancer cells. We report the molecular pharmacology and antitumor activity of PHT-427, a compound designed to bind to the pleckstrin homology (PH) binding domain of signaling molecules important in cancer. Although originally designed to bind the PH domain of Akt, we now report that PHT-427 also binds to the PH domain of PDPK1. A series of PHT-427 analogues with variable C-4 to C-16 alkyl chain length were synthesized and tested. PHT-427 itself (C-12 chain) bound with the highest affinity to the PH domains of both PDPK1 and Akt. PHT-427 inhibited Akt and PDPK1 signaling and their downstream targets in sensitive but not resistant cells and tumor xenografts. When given orally, PHT-427 inhibited the growth of human tumor xenografts in immunodeficient mice, with up to 80% inhibition in the most sensitive tumors, and showed greater activity than analogues with C4, C6, or C8 alkyl chains. Inhibition of PDPK1 was more closely correlated to antitumor activity than Akt inhibition. Tumors with PIK3CA mutation were the most sensitive, and K-Ras mutant tumors were the least sensitive. Combination studies showed that PHT-427 has greater than additive antitumor activity with paclitaxel in breast cancer and with erlotinib in non-small cell lung cancer. When given >5 days, PHT-427 caused no weight loss or change in blood chemistry. Thus, we report a novel PH domain binding inhibitor of PDPK1/Akt signaling with significant in vivo antitumor activity and minimal toxicity.

AB - Phosphatidylinositol 3-kinase/phosphatidylinositide-dependent protein kinase 1 (PDPK1)/Akt signaling plays a critical role in activating proliferation and survival pathways within cancer cells. We report the molecular pharmacology and antitumor activity of PHT-427, a compound designed to bind to the pleckstrin homology (PH) binding domain of signaling molecules important in cancer. Although originally designed to bind the PH domain of Akt, we now report that PHT-427 also binds to the PH domain of PDPK1. A series of PHT-427 analogues with variable C-4 to C-16 alkyl chain length were synthesized and tested. PHT-427 itself (C-12 chain) bound with the highest affinity to the PH domains of both PDPK1 and Akt. PHT-427 inhibited Akt and PDPK1 signaling and their downstream targets in sensitive but not resistant cells and tumor xenografts. When given orally, PHT-427 inhibited the growth of human tumor xenografts in immunodeficient mice, with up to 80% inhibition in the most sensitive tumors, and showed greater activity than analogues with C4, C6, or C8 alkyl chains. Inhibition of PDPK1 was more closely correlated to antitumor activity than Akt inhibition. Tumors with PIK3CA mutation were the most sensitive, and K-Ras mutant tumors were the least sensitive. Combination studies showed that PHT-427 has greater than additive antitumor activity with paclitaxel in breast cancer and with erlotinib in non-small cell lung cancer. When given >5 days, PHT-427 caused no weight loss or change in blood chemistry. Thus, we report a novel PH domain binding inhibitor of PDPK1/Akt signaling with significant in vivo antitumor activity and minimal toxicity.

UR - http://www.scopus.com/inward/record.url?scp=77949681661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949681661&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-09-0985

DO - 10.1158/1535-7163.MCT-09-0985

M3 - Article

C2 - 20197390

AN - SCOPUS:77949681661

VL - 9

SP - 706

EP - 717

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -